• Clene posted a net loss of USD 8.09 million for the quarter ended March 31, 2026, widening from USD 751,000 a year earlier.
• Operating loss narrowed 49% to USD 2.06 million as operating expenses fell 50% to USD 2.08 million.
• Revenue slid 81% to USD 15,000, reflecting a 98% drop in product revenue to USD 1,000.
• Other expense swung to USD 6.03 million from other income of USD 3.33 million on a USD 4.58 million loss on initial issuance of equity.
• Clene plans to submit an ALS NDA for CNM-Au8 in the third quarter of 2026 after FDA said proposed data may support accelerated approval, targeting Phase 3 RESTORE-ALS initiation in first quarter of 2027 as the post-approval confirmatory study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-016878), on May 14, 2026, and is solely responsible for the information contained therein.